

REACTIONS OF ALIPHATIC DIAZO COMPOUNDS XX.  
SYNTHESIS AND INVESTIGATION OF THE  
ANTISPASMODIC ACTIVITY OF ARYL-SUBSTITUTED  
 $\alpha$ -DIAZOKETONES

A. L. Fridman, V. S. Zalesov,  
N. A. Kolobov, and K. V. Dolbilkin


UDC 615.213:547.235.4

We carried out the synthesis of a series of substituted diazoketones and investigated their antispasmodic activity. The synthesis of the preparations was carried out by the method of Arndt and Eistert.



The investigation of aryl-substituted diazoacetones was of special interest because it is known that the amides of aryl-substituted acetic acids possess a rather high antispasmodic activity [1]. Both the already known aryl-substituted diazoketones (I-IV, VII, IX, Table 1) [2-6] and compounds which have not been described in the literature were synthesized for the investigation.

Our attempts to replace the chlorine in chlorodiazoacetone by nitrate, nitrile, carbonyl, succinimide, and other groups by reacting the diazoketone with the appropriate silver compounds failed. This is evidently explained by the decrease in the electrophilicity of the carbon bonded to the chlorine through a shift in the electron cloud, which envelops the conjugated  $\text{COCHN}_2$  system, toward the oxygen of the carbonyl group [7]. The introduction of a phenyl group into the chlorodiazoacetone molecule does not increase the mobility of the chlorine atom, and we also did not succeed in inducing phenylchlorodiazoacetone to react with the silver compounds mentioned above. The chlorine atom in diphenylchlorodiazoacetone becomes sufficiently mobile and is easily substituted by a nitrate group by the action of silver nitrate in an acetone-trile medium.



The compound obtained (VIII) is the first example in the series of nitroxy-substituted  $\alpha$ -diazoketones.


The absorption bands in the  $2125\text{--}2115\text{ cm}^{-1}$  region due to the diazo group and in the  $1660\text{--}1625\text{ cm}^{-1}$  region due to the conjugated carbonyl group are easily identified in the IR spectra (see Table 1) of the diazoketones. It is interesting that the introduction of a nitrate group into the diazoketone molecule leads to a shift in the carbonyl absorption band toward higher frequencies. This indicates that there is a decrease in the degree of  $p\text{--}\pi\text{--}p$  conjugation in the  $\text{COCHN}_2$  fragment through the electron acceptor properties of the nitrate group. A weakening of the conjugation in the diazocarbonyl fragment also takes place under the influence of the phenyl substituents; this is especially highly noticeable in the series phenyl-, diphenyl-, and triphenyldiazoacetones. A still greater effect is observed for  $\alpha$ -diazacetophenone because the aromatic ring in this case is an electron donor.

The antispasmodic activity of the  $\alpha$ -diazoketones we synthesized was investigated on mice using the maximum electroshock (seizure) test [8] and Corazol test [1, 9, 10].

Perm Pharmaceutical Institute. Translated from *Khimiko-Farmatsevticheskii Zhurnal*, Vol. 8, No. 11, pp. 29-32, November, 1974. Original article submitted February 20, 1973.

© 1975 Plenum Publishing Corporation, 227 West 17th Street, New York, N.Y. 10011. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission of the publisher. A copy of this article is available from the publisher for \$15.00.

TABLE 1. Substituted  $\alpha$ -Diazoketones  $\text{PCOCHN}_2$

| Com-<br>pound | R   | Yield<br>(in %) | Melting<br>point (in<br>deg) * * | IR spectrum (in $\text{cm}^{-1}$ ) |                         |
|---------------|---|-----------------|----------------------------------|------------------------------------|-------------------------|
|               |   |                 |                                  | $\nu \text{N}\equiv\text{N}$       | $\nu \text{C}=\text{O}$ |
| I             | $\text{C}_6\text{H}_5\text{CH}_2$   | 88              | 42—3                             | 2120                               | 1630                    |
| II            | $\text{C}_6\text{H}_5$  | 85              | 43—5                             | 2108                               | 1620                    |
| III           | $(\text{C}_6\text{H}_5)_2\text{CH}$   | 46              | 58—60                            | 2120                               | 1635                    |
| IV            | $(\text{C}_6\text{H}_5)_3\text{C}$  | 57              | 151—2                            | 2120                               | 1650                    |
| V             | $(\text{C}_6\text{H}_5)_2\text{CCl}$  | 45              | 45—7                             | 2125                               | 1625                    |
| VI            | $\text{C}_6\text{H}_5\text{CHCl}$   | 27              | 54—6                             | 2120                               | 1645                    |
| VII*          | $\text{C}_6\text{H}_5$  | 66              | 63—4                             | 2100                               | 1660                    |
| VIII          | $(\text{C}_6\text{H}_5)_2\text{CONO}_2$   | 36              | 82—3                             | 2120                               | 1660                    |
| IX            |  | 93              | 69—70                            | 2115                               | 1630                    |

\*The  $\alpha$ -hydrogen atom in compound VII is substituted by an acetyl group.

\*Compound I was crystallized from petroleum ether; II and VIII from hexane; III, V, and VII from ethanol; IV from toluene; VI from decane; and IX from methanol.

TABLE 2. Antispasmodic Activity of  $\alpha$ -Diazoketones

| Compound      | AU <sub>50</sub> (in mg/kg)* according to the maximum electroshock (seizure) test |
|---------------|---|
| I             | 107,0 (93,8—121,9)  |
| II            | not active  |
| III           | 225,0 (174,5—297,0)   |
| IV            | not active  |
| V             | not active  |
| VI            | 350,0 (296,0—113,0)   |
| VII           | 195,0 (175,0—216,4)   |
| VIII          | 220,0 (177,4—272,8)   |
| IX            | 740,0 (578,0—947,0)   |
| Phenobarbital | 15,5 (12,8—18,8)  |

\*The confidence limits of the  $AU_{50}$  were calculated for  $\rho = 0.05$ .

Spasms according to the maximum electroshock (seizure) test were brought about in the following way: silver electrodes were applied to the mouse's eye, an alternating electric current of 50 mA was passed through them for 0.2 sec with a vibrational frequency of 50 cycle/sec. This "dose" of electric current caused clonic-tonic spasms in all the mice. The antispasmodic action was judged by the (degree of) removal of the extensor phase of the spasmodic attack within  $1/2$ , 1, 2, 3, and 4 h after the injection of the preparations. The results were treated statistically by the method of Litchfield and Wilcoxon [11] while determining the  $AU_{50}$ . The fullest development of the antispasmodic activity of a preparation was judged from the lowest  $AU_{50}$  value (obtained) after its injection. The length of time it was active was taken as the peak of the antispasmodic action of the  $AU_{50}$  (dose) as determined by the maximum electroshock (seizure) test, and all further investigations in determining the antispasmodic and antitremor activity by other tests were carried out with this dose and at the peak of the activity.

The Corazol spasms were brought about by the intraperitoneal injection of 70 mg/kg of Corazol as a 0.7% aqueous solution in volumes of 0.1 ml for each 10 g of weight of the mouse. Spasms with a strength of three points develop in all the mice from this dose of Corazol; half of them die. The strength of the spasms are evaluated visually according to a three-point system: one point (is given) for clonic spasms with the mouse being in its natural posture; two points (are given) for clonic-tonic spasms with a forced convulsive movement of the mice and with the presence of positions unnatural for them during the spasms (on their side, on their back, etc.); three points (are given) for substantial clonic-tonic and tonic spasms when the mice are thrown upward during the spasmodic attacks, and when they fall, they do not maintain a posture that is natural for them; and the spasms also continue after they fall [10].

The antispasmodic activity of the preparations according to the Corazol test was judged from their ability, using an AU<sub>50</sub> dose as determined from the maximum electroshock (seizure) test, to prevent or decrease Corazol spasms by one or two points in all the mice used in the experiment.

The antitremor activity of the  $\alpha$ -diazoketones was determined by their ability, in AU<sub>50</sub> doses as determined by the maximum electroshock seizure test, to prevent the onset of tremor in the mice from nicotine at a dose of 8 mg/kg or arecoline at a dose of 30 mg/kg both of which were injected intraperitoneally as an aqueous solution in volumes of 0.1 ml for every 10 g of weight of the mouse.

The antispasmodic activity of the  $\alpha$ -diazoketones was compared to that for phenobarbital.

The  $\alpha$ -diazoketones were injected intraperitoneally as a 2% starch muclilage, because of their insolubility in water, in increasing doses up to 600 mg/kg. When there was no activity at a dose of 600 mg/kg, even if in only one animal of the group, the preparation was considered to be not active.

Their stimulating and depressing effects, on the central nervous system were determined visually.

Six of the nine  $\alpha$ -diazoketones investigated possess antispasmodic activity according to the maximum electroshock seizure test (Table 2). Thus,  $\alpha$ -diazoketones are a new class of preparations which manifest antispasmodic activity.

The peak of their antispasmodic effect for an  $AU_{50}$  dose, as determined by the maximum electroshock seizure test, is manifested within 2 h by diazoketone VIII and within 1 h by all the others. The  $\alpha$ -diazoketones are ranked as follows according to the strength of their antispasmodic activity: I > VII > VIII > III > VI > IX. All the diazoketones are 7-23 times less active than phenobarbital.

Compounds VI and VIII in  $AU_{50}$  doses, as determined by the maximum electroshock seizure test, also decrease Corazol spasms up to one point.

Thus, the introduction of a chlorine and nitrate group into phenyl-substituted  $\alpha$ -diazoketones broadens the spectrum of their antispasmodic activity (compare I, III with VI, VIII). The introduction of a chlorine (group) into phenyldiazoacetone (I) leads to a greater than three-fold decrease (VI) in antispasmodic activity, and the introduction of a chlorine (group) into diphenyldiazoacetone (III) leads to the loss of antispasmodic activity by the preparation (V). The antispasmodic activity also decreases when phenyl groups are introduced into compound I. Preparation III is less active than I, and triphenyldiazoacetone (IV) possesses no antispasmodic activity. The aryl-substituted diazoketones also lose their antispasmodic activity when the phenyl group is directly bonded to the carbonyl group (II), but the activity is restored when the  $\alpha$ -hydrogen atom is substituted in diazoketone II by an acetyl group (VII).

Preparations I, III, VI, and VIII in  $AU_{50}$  doses, as determined by the maximum electroshock seizure test, exert no antitremor activity according to the nicotine and arecoline tests when injected intraperitoneally into mice, i.e. they do not manifest H- and M-cholinolytic activity.

Compounds I, III, and VIII bring about a short-lived tranquilizing effect; VI effects stimulating activity in doses of more than 350 mg/kg, and VII causes a disruption of motor coordination in doses greater than 200 mg/kg.

Compounds I, III, and VI-IX did not kill any mice within one day when injected intraperitoneally in doses up to 600 mg/kg.

## EXPERIMENTAL

Aryl-Substituted  $\alpha$ -Diazoketones (I-VI). An ether solution of 0.1 mole of the acid chloride was slowly added with vigorous agitation at 0 to  $-5^{\circ}\text{C}$  to an ether solution of 0.3 mole of diazomethane. The reaction mixture was maintained for 1-2 h at room temperature, and the ether was distilled off along with the excess diazomethane. The remainder was recrystallized. Diazoketones I, II, III, IV, VII, and IX were identified by comparing them with previously known samples [2-6]. For V the following was found, %: C 66.54; H 4.12, N 9.89.  $C_{15}H_{11}ClN_2O$ . Calculated, %: C 66.50; H 4.07; N 10.37. For VI the following was found, %: C 55.42; H 3.60; N 14.31.  $C_9H_7ClN_2O$ . Calculated, %: C 55.67; H 3.61; N 14.43.

3-Nitroxy-3,3-diphenyl-1-diazoacetone (VIII). To 1 g of diazoketone V dissolved in 20 ml of acetonitrile was added with agitation a solution of 0.7 g of silver nitrate in 10 ml of acetonitrile. The reaction mixture was maintained for 30 min at room temperature, and the silver chloride precipitate was filtered off. The filtrate was evaporated to dryness in vacuo and the residue was recrystallized, m.p.  $82-83^{\circ}\text{C}$  (from hexane). Found, %: C 61.01; H 3.91; N 14.01.  $C_{15}H_{11}N_3O_4$ . Calculated, %: C 61.60; H 3.73; N 14.14. The frequencies of the following groups were detected in the IR spectrum:  $\nu N \equiv N$  2120,  $\nu CO$  1660, and  $\nu ONO_2$  1290  $\text{cm}^{-1}$ .

## LITERATURE CITED

1. V. S. Zalesov, *Farmakol. i Toksikol.*, No. 4, 419 (1963).
2. H. Sheffer and J. Moora, *J. Org. Chem.*, **28**, 129 (1963).
3. F. Arndt and B. Eistert, *Chem. Ber.*, **68**, 208 (1935).
4. A. Wilds et al., *Tetrahedron Letters*, No. 52, 4941 (1965).
5. R. Manfred, *Chem. Ber.*, **99**, 3128 (1966).

6. S. Tadashi, E. Shogi, and T. Takeshi, *Bull. Chem. Soc. Jap.*, 42, 1617 (1969).
7. A. L. Fridman, G. S. Ismagilova, V. S. Zalesov, et al., *Uspekhi Khim.*, 41, 722.
8. K. S. Raevskii, *Farmakol. i Toksikol.*, No. 4, 495 (1961).
9. V. S. Zalesov, *Ibid.*, No. 3, 282 (1964).
10. V. S. Zalesov, On the Antispasmodic Properties of Benzylamide and Its Derivatives [in Russian], Doctoral thesis, Perm', (1964).
11. M. L. Belel'kii, Elements of the Quantitative Determination of a Pharmacological Effect [in Russian], Riga (1959), p. 71.